Codexis, Inc. (Nasdaq: CDXS), a Redwood City, Calif.-based synthetic biology company, received a $50 million investment from Casdin Capital, LLC.
Casdin, a New York City-based life science-focused investment firm, has invested through the purchase of shares of Codexis’ common stock in a private placement.
Led by President and CEO John Nicols, Codexis is a protein engineering company that applies its proprietary CodeEvolver® technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and for use in molecular diagnostics.
Its technology enables improvements in protein performance, meeting customer needs for rapid, cost-effective and sustainable manufacturing in multiple commercial-scale implementations of biocatalytic processes.
FinSMEs
21/06/2019